admin – Lophos Pharmaceuticals

Lophos Pharma: Exploring the Potential of Mescaline

by admin in Press Releases February 24, 2022

Lophos Pharma is a Canadian peyote-focused psychedelics company. It was co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s potential in a range of indications, optimize the cultivation of peyote, and preserve the plant. It’s an ambitious plan in an emerging sector that has so far embraced the possibilities of compounds such […]

Lophos Pharmaceuticals Submits Application for Controlled Drugs and Substances Dealer’s License

by admin in Press Releases February 17, 2022

TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Lophos Holdings (The “Company”) is pleased to provide an update on its wholly owned subsidiary Lophos Pharmaceuticals (“Lophos”). Lophos is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). Lophos has made significant strides in launching operations at their recently acquired 10,000 square foot […]

G2 Acquires Lophos Pharma, a peyote focused psychedelics company

by admin in Press Releases January 21, 2022

TORONTO, Jan. 21, 2022 (GLOBE NEWSWIRE) — Greenridez 2.0 Acquisitions Corp. (the “Company“) is pleased to announce that it has completed its acquisition of psychedelic research company Lophos Pharma (“Lophos”). Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). The Company strongly supports Lophos Pharma’s belief in Peyote’s […]

All posts by: admin

Lophos Pharma: Exploring the Potential of Mescaline

Lophos Pharmaceuticals Submits Application for Controlled Drugs and Substances Dealer’s License

G2 Acquires Lophos Pharma, a peyote focused psychedelics company

EMAIL (GENERAL INQUIRY)

EMAIL (INVESTOR INQUIRY)